Major Adverse Cardiac Events at Follow-Up After Bare-Metal Stenting Versus Drug-Eluting Stenting in ST-Elevated Myocardial Infarction

American Journal of Cardiology

Volumn 103, Issue 12, 2009, Pages 1672-1674

  Pierre Louis, Bredy ^a   Aronow, Wilbert S ^a   Palaniswamy, Chandrasekar ^a   Singh, Tarunjit ^a   Ahn, Chul ^b   Asija, Amit ^a   Weiss, Melvin B ^a   Kalapatapu, Kumar ^a   Pucillo, Anthony L ^a   Monsen, Craig E ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN; TENECTEPLASE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG ELUTING STENT; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG-ELUTING STENTS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEW YORK; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 67649394231     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.02.016     Document Type: Article

References (13)

1. Lip G.Y.H., and Blann A.D. Thrombogenesis and fibrinolysis in acute coronary syndromes: important facets of a prothrombotic or hypercoagulable state. J Am Coll Cardiol 36 (2000) 2044-2046
2. Merlini P.A., Bauer K.A., Oltrona L., Arddissino D., Spinola A., Cattaneo M., Broccolino M., Mannucci P.M., and Rosenberg R.D. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 25 (1995) 203-209
3. Gurbel P.A., Serebruany V.L., Shustov A.R., Bahr R.D., Carpo C., Ohman E.M., and Topol E.J. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction. J Am Coll Cardiol 311 (1998) 466-473
4. Dunn C.J., and Goa K.L. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am J Cardiovascular Drugs 1 (2001) 51-66
5. Kirtane A.J., Weisbord A., Karmpaliotis D., Murphy S.A., Giugliano R.P., Cannon C.P., Antman E.M., Ohman E.M., Roe M.T., Braunwald E., et al., TIMI Study Group. Relation of impaired thrombolysis in myocardial infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am J Cardiol 95 (2005) 224-227
6. Harjai K.J., Grines C., Stone G.W., Boura J., Turco M., Brodie B., Sadeghi M., Cox D., Grines L., O'Neill W.W., and Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Frequency, determinants, and clinical implications of residual intracoronary thrombus following primary angioplasty for acute myocardial infarction. Am J Cardiol 92 (2003) 377-382
7. Hong M.-K., Mintz G.S., Lee C.W., Park D.-W., Park K.-M., Lee B.-K., Kim Y.-H., Song J.-M., Han K.-H., Kang D.-H., et al. Late stent malposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 113 (2006) 414-419
8. Hong M.-K., Mintz G.S., Lee C.W., Lee B.K., Kim Y.-H., Lee S.-W., Song J.-M., Han K.-H., Kang D.-H., Song J.-K., et al. Incidence, mechanism, predictors, and long-term prognosis of late stent malposition after bare-metal stent implantation. Circulation 109 (2004) 881-886
9. Fujimoto H., Tao S., Mitani H., Ito S., Fujimoto Y., Maehara A., Ishiwata S., Yamaguchi T., and Ohno M. The efficacy of bare metal stent implantation for patients with acute myocardial infarction in the drug-eluting stent era. J Cardiol 51 (2008) 189-195
10. Brodie B.R., Stuckey T., Downey W., Humphrey A., Nussbaum M., Laurent S., Bradshaw B., Metzger C., Hermiller J., Krainin F., et al., Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Outcomes with drug-eluting versus bare-metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Catheter Cardiovascular Interv 72 (2008) 893-900
11. Mauri L., Hsieh W.-H., Massaro J.M., Ho K.K.L., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
12. Luscher T.F., Steffel J., Eberli F.R., Joner M., Nakazawa G., Tanner F.C., and Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
13. Mauri L., Silbaugh T.S., Garg P., Wolf R.E., Zelevinsky K., Lovett A., Varma M.R., Zhou Z., and Normand S.-L.T. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359 (2008) 1330-1342